Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.64 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22015926 | 1.00 | PTGS1 (0.64) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL20077213 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL20077231 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL22015695 | 0.86 | NOD1 (0.56) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL22015849 | 0.86 | NOD1 (0.56) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL22015828 | 0.86 | PTGS1 (0.64) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL22015660 | 0.86 | PTGS1 (0.64) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL15473350 | 0.83 | PTGS1 (0.75) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL14850413 | 0.83 | PTGS1 (0.75) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL12181828 | 0.83 | PTGS1 (0.75) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008287-B2 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine | EPICENTRX, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200157047-A1 | SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE | EPICENTRX, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008287-B2 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine | AS3MT, SLC10A6, SLCO1B3 | PTGS1 3711/4885GSTK1 737/4885GLO1 1067/4885 |
| US-20200157047-A1 | SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE | AS3MT, SLC10A6, SLCO1B3 | PTGS1 3711/4885GSTK1 737/4885GLO1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.